论文部分内容阅读
利妥希玛（ｒｉｔｕｘｉｍａｂ，ＭａｂＴｈｅｒａ）是由罗氏公司开发上市的一种单克隆抗体抗癌药。近来已有众多有关该药引起严重不良反应的报道。其中包括８例因细胞活素释放综合征（ＣＲＳ）致死病例。鉴于此，欧洲医药评估局（ＥＭＥＡ）要求罗氏公司加强该产品的标签说明
Rituximab (MabThera) is a monoclonal antibody developed and marketed by Roche. There have been many reports of serious side effects of the drug recently. Including 8 cases of death due to cytokine release syndrome (CRS). In view of this, the European Medical Evaluation Agency (EMEA) asked Roche to strengthen the labeling of the product